Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: n-3 control Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease

NCT04088240
View directory record Official record
Conditions
Elevated Triglycerides, Cardiovascular Risk Factor
Interventions
DPA enriched n-3, n-3 control, Placebo
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

NCT02210000
View directory record Official record
Conditions
Gastroparesis
Interventions
Placebo, Camicinal
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Chandler, Arizona • Long Beach, California • Northridge, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Not applicable Interventional

Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients

NCT00002012
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon alfa-n3
Drug
Lead sponsor
Interferon Sciences
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

NCT01262898
View directory record Official record
Conditions
Gastroparesis
Interventions
GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet), Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Concord, California • Indianapolis, Indiana • Chevy Chase, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 1, 2026, 10:42 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

NCT03077477
View directory record Official record
Conditions
Neoplasms, Medication Toxicity, Tolerance
Interventions
AMXT 1501, Placebo Oral Tablet
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study

NCT01934192
View directory record Official record
Conditions
Gastroparesis
Interventions
GSK962040 50 mg, Metoclopramide 10 mg, Placebo NG, Placebo IV
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Aurora, Colorado • Augusta, Georgia • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 1, 2026, 10:42 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

NCT05045482
View directory record Official record
Conditions
Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
Interventions
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Phase 3 Interventional Results available

Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer

NCT00360971
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
Interventions
palifermin, cisplatin, placebo, neck dissection, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Scottsdale, Arizona • Auburn, California • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Not applicable Interventional

n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy

NCT05145452
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
Fish-oil derived n-3 polyunsaturated fatty acids
Dietary Supplement
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
55 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Bioavailability of EPA and DHA From Two Dietary Supplements

NCT01908374
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
DHA-rich fish oil versus Phospholipid-rich fish oil
Dietary Supplement
Lead sponsor
Arctic Nutrition AS
Industry
Eligibility
18 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Not applicable Interventional

Combining HIIT and n-3 PUFA to Reduce Inflammation and Improve Metabolic Health

NCT05295719
View directory record Official record
Conditions
Obesity, Inflammation, Human Microbiome, Insulin Resistance, Dyslipidemias
Interventions
Omega-3 polyunsaturated fatty acid, High-Intensity Interval Training, Safflower oil, Low-intensity training
Dietary Supplement · Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acids for Autism Treatment

NCT00786799
View directory record Official record
Conditions
Autism
Interventions
Omega-3 Fatty Acids
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 8 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

NCT01821833
View directory record Official record
Conditions
Breast Cancer, Ovarian Neoplasm, Pain
Interventions
Omega-3 fatty acid, Placebo, Paclitaxel
Dietary Supplement · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 1, 2026, 10:42 AM EDT
Recruiting Phase 2 Interventional

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

NCT06671054
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg, AP1189 matching placebo
Drug
Lead sponsor
SynAct Pharma Aps
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Cutler Bay, Florida • Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 1, 2026, 10:42 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers

NCT00682318
View directory record Official record
Conditions
Healthy
Interventions
Fish Oil, Safflower Oil, Ethanol, Omega-3 polyunsaturated fatty acids, Omega-6 polyunsaturated fatty acid
Drug · Dietary Supplement
Lead sponsor
Carsten Skarke, MD
Other
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Obesity and Caries in Young South Asian Children: A Common Risk Factor Approach

NCT03077425
View directory record Official record
Conditions
Pediatric Obesity, Early Childhood Caries
Interventions
Enhanced Usual Care (EUC), Intervention
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
3 Months to 2 Years
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
8
States / cities
East Windsor, New Jersey • New Brunswick, New Jersey • Jamaica, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

NCT01869764
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Male Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 1, 2026, 10:42 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

NCT05875948
View directory record Official record
Conditions
Hepatorenal Syndrome, Acute Kidney Injury
Interventions
R2R01, Terlipressin
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

NCT06735209
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

NCT01336738
View directory record Official record
Conditions
Diabetes, Type 2
Interventions
Placebo, 150 mg PF-04991532, 450 mg PF-04991532, 750 mg PF-04991532, Sitagliptin 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Jonesboro, Arkansas • Los Angeles, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Not applicable Interventional

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3

NCT00000844
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon alfa-n3, Interferon alfa-n1
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
15
States / cities
Los Angeles, California • Redwood City, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis

NCT01240915
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
placebo, MultiStem low dose, MultiStem high dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
37
States / cities
San Francisco, California • Lafayette, Colorado • Lakewood, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Disease Risk Reduction and Omega-3 Rich Rainbow Trout (Fish for Health)

NCT02204709
View directory record Official record
Conditions
Obesity
Interventions
2N Trout, 3N Trout, Tilapia
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
20 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Sep 1, 2026, 10:42 AM EDT